SCHEDULE 13G: State Street Corporation Discloses 4.4% Passive Stake in REGENXBIO INC
Beneficial Ownership Disclosure
State Street Corporation has disclosed a 4.4% beneficial ownership stake in REGENXBIO INC, holding 2,185,851 shares as of December 31, 2024, primarily through shared voting and dispositive power.
Summary
- State Street Corporation filed a Schedule 13G with the SEC, reporting its beneficial ownership in REGENXBIO INC.
- As of December 31, 2024, State Street Corporation beneficially owned 2,185,851 shares of REGENXBIO INC common stock.
- This ownership represents 4.4% of the total class of securities.
- State Street Corporation holds shared voting power over 2,035,671 shares and shared dispositive power over 2,185,851 shares.
- The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
- The beneficial ownership is held through various subsidiaries, including SSGA FUNDS MANAGEMENT, INC., STATE STREET GLOBAL ADVISORS EUROPE LIMITED, STATE STREET GLOBAL ADVISORS LIMITED, STATE STREET GLOBAL ADVISORS TRUST COMPANY, and STATE STREET GLOBAL ADVISORS, LTD., all classified as Investment Advisers.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing (Schedule 13G) disclosing an institutional ownership stake, which is neutral in sentiment as it does not contain performance data, strategic updates, or any unexpected events.
Positives
- The filing provides transparency regarding institutional ownership in REGENXBIO INC.
- It confirms State Street Corporation's investment in the company, indicating a level of confidence from a major institutional investor.
Future Outlook
The document is a disclosure of current ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This filing is a routine disclosure by a major global financial services company, State Street Corporation, indicating a passive investment in REGENXBIO INC. It reflects the ongoing portfolio management activities of large institutional investors within the broader market, rather than a specific strategic move related to REGENXBIO's industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding the ownership structure and the presence of a significant institutional investor.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of the event which required the filing of this statement (end of reporting period). |
| 01/31/2025 | Date of filing of the Schedule 13G statement. |
Keywords
REGENXBIO INC, State Street Corporation, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing, asset management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.